p28 in Treating Younger Patients With Recurrent or Progressive Central Nervous System Tumors

Inclusion Criteria:

• Patients must have histologically confirmed primary progressive, recurrent orrefractory CNS tumors with no known curative therapies limited to high grade glioma,such as glioblastoma multiforme, medulloblastoma, primitive neuroectodermal tumor,atypical teratoid/rhabdoid tumor, anaplastic astrocytoma, high-grade astrocytoma nototherwise specified (NOS), anaplastic oligodendroglioma, or choroid plexus carcinoma;or diffuse intrinsic pontine glioma; the requirements for histological verificationare waived for diffuse intrinsic pontine glioma

• Patients must not have received myelosuppressive chemotherapy or immunotherapy within 3 weeks of registration (6 weeks if prior nitrosourea)

• Patients must have received their last dose of biologic agent >= 7 days prior to studyregistration

• Steroid dose should be stable or decreasing for at least 1 week prior to registration

• If prior therapy was monoclonal antibody, 30 days or 3 half-lives must have elapsed (whichever is longer), prior to registration

• Patient must be off all colony stimulating factors > 1 week prior to registration (filgrastim [GCSF], sargramostim [GM CSF], erythropoietin)

• Any craniospinal irradiation must have taken place >= 3 months prior to registration >= 8 weeks for local irradiation to primary tumor; >= 2 weeks prior to study entry forfocal irradiation for symptomatic metastatic sites

• Karnofsky performance scale (KPS) (for > 16 years [yrs] of age) or Lansky performancescore (LPS) (for =< 16 years of age) >= 50 assessed within two weeks prior toregistration

• Patients with neurological deficits should have deficits that are stable for a minimumof 1 week prior to registration

• Absolute neutrophil count >= 1000/ mm^3 (unsupported)

• Platelets >= 100,000/ mm^3 (unsupported)

• Hemoglobin >= 8g/dL (with or without packed red blood cells [PRBC] transfusion)

• Total bilirubin =< 1.5 times upper limit of normal for age

• Alanine aminotransferase (ALT) (serum glutamate pyruvate transaminase [SGPT]) =< 3.0times institutional upper limit of normal for age

• Aspartate aminotransferase (AST) (serum glutamic oxaloacetic transaminase [SGOT]) =< 3.0 times institutional upper limit of normal for age

• Blood glucose within normal limits for age (If above institutional normal limits mustbe repeated as fasting and then within normal limits [WNL] for age)

• Creatinine clearance or nuclear glomerular filtration rate (GFR) >= 70 mL/min/1.73 m^2or a serum creatinine based on age as follows:

• =< 5 years: 0.8 mg/dL

• > 5 to =< 10 years: 1 mg/dL

• > 10 to =< 15 years: 1.2 mg/dL

• > 15 years: 1.5 mg/dL

• Albumin >= 2 g/dL

• Female patients of childbearing potential must not be pregnant or breast-feeding;female patients of childbearing potential must have a negative serum or urinepregnancy test

• Patients of childbearing or child fathering potential must be willing to use amedically acceptable form of birth control, which includes abstinence, while beingtreated on this study and for 6 months after the last drug administration

• Ability of subject or parent/guardian to understand and the willingness to sign awritten informed consent document

Exclusion Criteria:

• Patients who are receiving any other investigational agents

• Patients with known inability to return for follow-up visits or obtain follow-upstudies required to assess toxicity to therapy

• Only tumor types listed above are allowed; low grade gliomas (with and withoutneurofibromin 1 [NF1]) and ependymomas are excluded

• History of hypersensitivity reactions attributed to compounds of similar chemical orbiologic composition to murine protein-containing products

• Uncontrolled intercurrent illness including, but not limited to, ongoing or activeinfection, symptomatic congestive heart failure, unstable angina pectoris, cardiacarrhythmia, or psychiatric illness/social situations that would limit compliance withstudy requirements

• Pregnant women are excluded from this study; breastfeeding should be discontinued ifthe mother is treated with p28